Motus GI Holdings, Inc. announced the publication of positive data from a study of the second generation Pure-Vu System in a manuscript titled, ?An intraprocedural bowel cleansing system for difficult-to-prepare patients?A multicenter prospective feasibility study,? in the peer-reviewed journal, United European Gastroenterology (UGE). The Company?s Pure-Vu System is an FDA-approved and CE-certified bowel cleansing system (BCS) intended to increase visualization in inadequately prepared colons by offering intraprocedural cleansing.

The single arm, international, multicenter colonoscopy study evaluated if an adequate level of bowel cleansing could be achieved with the Pure-Vu System in patients with previous poor bowel preparation (Boston Bowel Preparation Scale (BBPS)<6). The study enrolled a total of 44 patients with previous poor bowel preparation (BBPS<6) within the last 2 years. Typically patients with a history of poor bowel prep are prescribed a more aggressive prep regime on their follow up colonoscopy, whereas in this study all patients received a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.

The BBPS was assessed before and after segmental washing by the endoscopist who performed the procedure and later by an independent endoscopist (photos). The study exclusion criteria included previous colon resection, previous colorectal cancer, colitis, lower gastrointestinal bleeding with hemodynamic instability, ASA>3, insufficiently corrected anticoagulation disorders, inability to provide informed consent.